Organon & Co. (NYSE:OGN) Upgraded to Neutral at Piper Sandler

Key Points

• Piper Sandler upgraded Organon from "underweight" to "neutral" and raised its price target from $5.00 to $14.00, implying roughly a 6.42% upside from the current stock price.
• Sun Pharma agreed to acquire Organon for $14.00/share (≈$11.75B), which drove the stock to a 52‑week high and heavy call buying, but multiple shareholder law firms have opened investigations that could prompt litigation, delays, or renegotiation.

Organon & Co. (NYSE:OGN - Get Free Report) was upgraded by equities research analysts at Piper Sandler from an "underweight" rating to a "neutral" rating in a research note issued on Tuesday, MarketBeat.com reports. The firm currently has a $14.00 price objective on the stock, up from their prior price objective of $5.00. Piper Sandler's price objective would indicate a potential upside of 6.42% from the stock's current price.

A number of other equities research analysts have also recently weighed in on the company. Wall Street Zen cut Organon & Co. from a "buy" rating to a "hold" rating in a research note on Saturday, January 31st. Barclays lifted their price objective on Organon & Co. from $7.50 to $8.00 and gave the company an "underweight" rating in a research note on Tuesday, February 24th. Finally, Zacks Research raised Organon & Co. from a "strong sell" rating to a "hold" rating in a research note on Tuesday, April 14th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of "Reduce" and a consensus price target of $10.75.

Organon & Co. Trading Up 16.8%

Shares of NYSE OGN opened at $13.16 on Tuesday. Organon & Co. has a twelve month low of $5.69 and a twelve month high of $13.24. The company has a current ratio of 1.82, a quick ratio of 1.23 and a debt-to-equity ratio of 11.47. The stock has a fifty day simple moving average of $7.33 and a 200-day simple moving average of $7.66. The stock has a market capitalization of $3.42 billion, a PE ratio of 18.53, a PEG ratio of 1.04 and a beta of 0.67.

Organon & Co. (NYSE:OGN - Get Free Report) last issued its quarterly earnings data on Thursday, February 12th. The company reported $0.63 earnings per share for the quarter, missing analysts' consensus estimates of $0.73 by ($0.10). Organon & Co. had a net margin of 3.01% and a return on equity of 122.01%. The firm had revenue of $1.51 billion during the quarter, compared to analyst estimates of $1.52 billion. During the same period in the previous year, the firm posted $0.90 earnings per share. The company's quarterly revenue was down 5.3% compared to the same quarter last year. On average, equities analysts forecast that Organon & Co. will post 3.23 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the business. Foster Dykema Cabot & Partners LLC purchased a new stake in shares of Organon & Co. in the 3rd quarter valued at about $29,000. Farther Finance Advisors LLC lifted its holdings in shares of Organon & Co. by 87.8% in the 4th quarter. Farther Finance Advisors LLC now owns 4,349 shares of the company's stock valued at $31,000 after purchasing an additional 2,033 shares during the last quarter. Rothschild Investment LLC raised its stake in Organon & Co. by 73.1% during the 3rd quarter. Rothschild Investment LLC now owns 3,899 shares of the company's stock valued at $42,000 after acquiring an additional 1,646 shares during the last quarter. Eurizon Capital SGR S.p.A. purchased a new stake in Organon & Co. during the 4th quarter valued at approximately $44,000. Finally, Kestra Advisory Services LLC purchased a new stake in Organon & Co. during the 4th quarter valued at approximately $47,000. 77.43% of the stock is owned by institutional investors and hedge funds.

Organon & Co. News Summary

Here are the key news stories impacting Organon & Co. this week:

• Positive Sentiment: Sun Pharma agreed to buy Organon for $14.00/share in an all‑cash deal (~$11.75B), providing a clear exit price and driving the rally. Sun Pharma to acquire Organon
• Positive Sentiment: Market reaction: OGN traded to a 52‑week high and saw sharp intraday gains as investors priced in the takeover premium. Organon Soars to 52-Week High on Sun Merger
• Positive Sentiment: Options flow: unusually large call buying was reported ahead of/after the deal, consistent with aggressive bullish positioning. (Elevates short‑term upside/premium capture for speculators.)
• Neutral Sentiment: Strategic rationale: Sun Pharma cites Organon’s scale in women’s health, biosimilars and global commercial footprint as the rationale — that supports long‑term logic but integration and leverage risks remain. CNBC: Sun Pharma to buy Organon
• Negative Sentiment: Multiple shareholder law firms have opened investigations into whether Organon’s board obtained a fair price and fulfilled fiduciary duties; these probes could lead to litigation, deal delay, or renegotiation. Halper Sadeh Investigating Organon Deal Johnson Fistel Investigates

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.